32 results
8-K
EX-1.1
PCSA
Processa Pharmaceuticals Inc
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
), neither (A) the Time of Sale Disclosure Package (as defined below) nor (B) any issuer free writing prospectus (as defined below), when considered … together with the Time of Sale Disclosure Package, included an untrue statement of a material fact or omitted to state a material fact necessary in order
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
29 Oct 14
Entry into a Material Definitive Agreement
12:00am
the right to design and employ such promotional materials including, without limitation, any packaging, labeling, advertising. marketing, package
8-K
EX-10.1
mqae4hd
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
8-K
xcce 34jsx
12 Oct 17
Entry into a Material Definitive Agreement
12:00am
424B4
rwua4jb
29 Jan 24
Prospectus supplement with pricing info
4:15pm